Johnson & Johnson's long-term prospects are promising due to strong drug pipeline developments and significant R&D ...

In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...

Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...

We think SPH is in a good financial position. In the past three years, its debt over capital has been stable at around 0.4 times. Despite not being in a net cash position, it has enough cash to ...

Rocket Lab (NASDAQ: RKLB) shareholders received some wonderful news Thursday night when the U.S. Department of Defense ...

Rocket Lab USA shares were 6% higher, to $19.40, after the company said it has been selected by the U.S. Space Force to compete for the Department of Defense's highest-priority national security ...

Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...

Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...

German airline Lufthansa's air freight business said on Friday it is experiencing an increase in demand for pharmaceutical ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...